within Pharmacolibrary.Drugs.ATC.L;

model L01FX05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.4283333333333335e-05,
    adminDuration  = 600,
    adminMass      = 1.8 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00607,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0075899999999999995,
    k12             = 4.19,
    k21             = 4.19
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FX05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Brentuximab vedotin is an antibody-drug conjugate targeting CD30, used primarily for the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It is approved and widely used in current clinical practice for relapsed or refractory cases and for some front-line regimens.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult patients with malignant lymphomas, following single and multiple intravenous infusions.</p><h4>References</h4><ol><li><p>Zhang, D, et al., &amp; Chia, YL (2024). Time-varying brentuximab vedotin pharmacokinetics and weight-based dosing in paediatric patients despite lower exposure in those aged 2 to &lt;6 and 6-11 years. <i>British journal of clinical pharmacology</i> 90(9) 2299–2313. DOI:<a href=\"https://doi.org/10.1111/bcp.16128\">10.1111/bcp.16128</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38866401/\">https://pubmed.ncbi.nlm.nih.gov/38866401</a></p></li><li><p>Zhao, B, et al., &amp; Han, TH (2016). Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. <i>British journal of clinical pharmacology</i> 82(3) 696–705. DOI:<a href=\"https://doi.org/10.1111/bcp.12988\">10.1111/bcp.12988</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27115790/\">https://pubmed.ncbi.nlm.nih.gov/27115790</a></p></li><li><p>Han, TH, et al., &amp; Engert, A (2013). Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. <i>Cancer chemotherapy and pharmacology</i> 72(1) 241–249. DOI:<a href=\"https://doi.org/10.1007/s00280-013-2192-z\">10.1007/s00280-013-2192-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23719719/\">https://pubmed.ncbi.nlm.nih.gov/23719719</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FX05;
